Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 24, 2009

Biogen Idec Signs Up to Help Aveo Develop Its Discovery-Stage Cancer Program

  • Aveo Pharmaceuticals and Biogen Idec are working together to develop Aveo's discovery-stage ErbB3-targeted antibodies to treat cancer. Biogen Idec will reserve the option at proof-of-concept to exercise development and commercialization rights to ErbB3 binding antibodies for territories outside of North America. AVEO retains all North American commercialization rights.

    Aveo will receive an up-front payment and is eligible to receive milestone payments based upon the achievement of specified development goals and remains in charge of global development of the ErbB3 program.

    "This agreement for the development and commercialization of our discovery-stage ErB3-targeted antibodies facilitates our strategy to develop a balanced portfolio of small molecule drugs and antibodies for the treatment of cancer," says Tuan Ha-Ngoc, president and CEO of AVEO.

    ErbB3 is a type 1 tyrosine kinase receptor of the EFGR family that is widely expressed in human carcinomas, with demonstrated overexpression correlated with poor prognosis in several different tumor types.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »